Identification of potential metabolic biomarkers of rectal cancer and of the effect of neoadjuvant radiochemotherapy

Identifier:  imarina:9216861

Handle: https://hdl.handle.net/20.500.11797/imarina9216861

Authors:  Rodríguez-Tomàs, E; Arenas, M; Gómez, J; Acosta, J; Trilla, J; López, Y; Arquez, M; Torres, L; Araguas, P; Hernández-Aguilera, A; Baiges-Gaya, G; Castañé, H; Camps, J; Joven, J

Abstract:
We report a pilot study on the feasibility of determinations of circulating levels of paraoxonase-1 (PON1) and compounds related to energy metabolism as biomarkers for the evaluation of patients with rectal cancer (RC), and the effects produced by neoadjuvant radiochemotherapy (NRCT). We studied 32 patients treated with radiotherapy plus capecitabine concomitant chemotherapy and 48 control subjects. We identified pre-NRCT PON1 and alpha-ketoglutarate as the parameters that best discriminated between RC patients and the control group. Receiver operating characteristics analysis of the combination of the two parameters showed an area under the curve (AUC) of 0.918. Moreover, patients who presented a pathological complete response (pCR) to treatment had lower plasma pre-NRCT valine concentrations (AUC of 0.826). Patients who had a relapse had lower concentrations of succinate (AUC of 0.833). The results of the present study illustrate the usefulness of investigating alterations in oxidative stress and metabolism in RC. Due to the small number of patients studied, our results must be considered preliminary, but they suggest that the determination of circulating levels of PON1 and alpha-ketoglutarate might be a valuable tool for the early diagnosis of RC, while the determination of valine and succinate might effectively predict pCR and the appearance of relapse.